Journal Review in Thoracic Surgery: Adjuvant Therapy in Lung Adenocarcinoma

November is Lung Cancer Awareness Month, and what better way is there to spend your time than getting to know the recent advances in adjuvant therapy for early-stage lung adenocarcinoma? 



Learning Objectives



-        Review work-up and treatment of lung adenocarcinoma

-        Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease

-        Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy

-        Discuss future directions for research

-        Discuss additional advancements in diagnosis, monitoring, and immunotherapy



Referenced Material



-        Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071  https://www.nejm.org/doi/full/10.1056/NEJMoa2027071

-        Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015

https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext

-        Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008

https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext



Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.